Publications by authors named "Mark L Cunningham"

Claim this Profile
M
Monoacylglycerol Lipase Inhibition in Human and Rodent Systems Supports Clinical Evaluation of Endocannabinoid Modulators.
Jason R Clapper, Cassandra L Henry, Micah J Niphakis, Anna M Knize, Aundrea R Coppola, Mark L Cunningham

J Pharmacol Exp Ther· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tricyclic GyrB/ParE (TriBE) inhibitors: a new class of broad-spectrum dual-targeting antibacterial agents.
Leslie W Tari, Xiaoming Li, Michael Trzoss, Daniel C Bensen, Zhiyong Chen, Mark L Cunningham

PLoS One· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anthracimycin activity against contemporary methicillin-resistant Staphylococcus aureus.
Mary E Hensler, Kyoung Hwa Jang, Wdee Thienphrapa, Lisa Vuong, Dan N Tran, Mark L Cunningham

J Antibiot (Tokyo)· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines.
Thanh Lam, Mark T Hilgers, Mark L Cunningham, Bryan P Kwan, Kirk J Nelson

J Med Chem· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinguishing on-target versus off-target activity in early antibacterial drug discovery using a macromolecular synthesis assay.
Mark L Cunningham, Bryan P Kwan, Kirk J Nelson, Daniel C Bensen, Karen J Shaw

J Biomol Screen· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE), Part II: development of inhibitors with broad spectrum, Gram-negative antibacterial activity.
Micheal Trzoss, Daniel C Bensen, Xiaoming Li, Zhiyong Chen, Thanh Lam, Mark L Cunningham

Bioorg Med Chem Lett· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity.
Leslie W Tari, Michael Trzoss, Daniel C Bensen, Xiaoming Li, Zhiyong Chen, Mark L Cunningham

Bioorg Med Chem Lett· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of bacteria-selective threonyl-tRNA synthetase substrate inhibitors by structure-based design.
Min Teng, Mark T Hilgers, Mark L Cunningham, Allen Borchardt, Jeffrey B Locke

J Med Chem· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of enzymology in a structure-based drug discovery program: bacterial DNA gyrase.
Mark L Cunningham

Methods Mol Biol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani.
Susan Wyllie, Mark L Cunningham, Alan H Fairlamb

J Biol Chem· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of quinonoid-dihydropteridine reductase (QDPR) from the lower eukaryote Leishmania major.
Lon-Fye Lye, Mark L Cunningham, Stephen M Beverley

J Biol Chem· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis